Amgen Inc (NASDAQ: AMGN) reported third-quarter 2019 adjusted EPS of $3.66 on revenue of $5.74 billion. This was better than analysts’ prediction of earnings of $3.53 per share on revenues of $5.63 billion. Amgen stock advanced about 0.2% during the after-hours.
Revenues for the quarter reflected a 3% decline over last year, due to the impact of biosimilar and generic competition against key products. Total product sales edged down 1%.
CEO Robert Bradway said, “We continue to advance numerous first-in-class medicines in our pipeline, while also pursuing external opportunities that will contribute to our long-term growth, such as our pending acquisition of Otezla.”
Amgen raised its outlook on full-year 2019 revenue to a range of $22.8 billion – $23.0 billion, from the earlier range of $22.4 billion – $22.9 billion. The company also raised the guidance on GAAP and Non-GAAP earnings.
Amgen currently expects full year adjusted EPS of $14.20 to $14.45, versus the prior estimate of $13.75 to $14.30. On a GAAP basis, Amgen is projected to earn $12.50 to $12.80 in fiscal 2019, higher than the initial projection of $12.10 to $12.71
READ: After a 2-month stock slide, Q3 could bring Alteryx’s deflection point
Rival drugmaker Pfizer (NYSE: PFE) yesterday reported lower revenues and earnings for the third quarter. The results, however, topped the market’s expectations. Merck (NYSE: MRK) also surpassed analysts’ expectations yesterday helped by oncology and vaccines.
The quarterly results come two months after Amgen announced that it would acquire Celgene’s (NASDAQ: CELG) Otezla business for $13.4 billion in a cash transaction. Amgen expects the addition of OTEZLA to positively impact its financial results, including an immediate accretion to its non-GAAP EPS.
AMGN shares have gained 8% since the beginning of this year and 11% in the past 12 months.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Shifting demand and margins in focus as Fastenal (FAST) prepares for Q4 report
Fastenal Company (NASDAQ: FAST) is gearing up to publish its fourth-quarter 2025 financial results, after effectively navigating an evolving market environment. The report is expected to shed light on the company's
Constellation Brands (STZ) gets through another difficult quarter with few gains
Shares of Constellation Brands (NYSE: STZ) stayed red on Friday. The stock has gained 4% in the past three months. The beverage company saw its sales and profits decline in
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
Comments
Comments are closed.